Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
ARD Podcast
Claim This Podcastby BMJ Group
4.5(4 reviews)
25 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇩🇪
Podcast Overview
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Language
🇺🇲
Publishing Since
7/3/2014
Reach the team behind ARD Podcast
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
June 21, 2024
Use of imaging in large vessel vasculitis: EULAR 2023 update
<p>Join our host Dr. Fabian Proft, ARD's Social Media Advisor, as he discusses the <a href='https://ard.bmj.com/content/83/6/741'>updated 2023 EULAR recommendations for imaging </a><a href='https://ard.bmj.com/content/83/6/741'>in large vessel vasculitis (LVV)</a> with Professor Christian Dejaco and Dr. Milena Bond, the lead authors of the manuscript. This episode covers the latest evidence on ultrasound, MRI, CT, and FDG-PET for diagnosing and monitoring LVV.</p> <p> Key highlights include:</p> <ul><li>Ultrasound as the first-line imaging test for giant cell arteritis.</li> <li>Preferred imaging modalities for Takayasu arteritis.</li> <li>Use of imaging for assessing vessel abnormalities and long-term monitoring.</li> <li>Insights into the research agenda for imaging in large vessel vasculitides.</li> </ul> <p>Tune in to learn how these updates aim to enhance patient care and stay informed on the latest developments in rheumatology imaging. Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - <a href='https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059'>https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059</a> .</p>
April 22, 2024
Managing Systemic Lupus Erythematosus: the latest EULAR recommendations
<p>This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE).</p> <p>ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: <a href='https://ard.bmj.com/content/83/1/15'>https://ard.bmj.com/content/83/1/15</a>.</p> <p>Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - <a href='https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059'>https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059</a> .</p>
October 30, 2023
A non-pharma approach in systemic lupus erythematosus and systemic sclerosis
<p>In this podcast, we discuss the evidence-based EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professor Carina Boström and Professor Ioannis Parodis, both from the Karolinska Institutet and the Karolinska University Hospital, Stockholm, Sweden, about their recent paper. Read it on the ARD website: <a href='https://ard.bmj.com/content/early/2023/08/23/ard-2023-224416'>https://ard.bmj.com/content/early/2023/08/23/ard-2023-224416</a></p> <p>Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page -<a href='https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059'>https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059</a> .</p> <p> </p>
25 total episodes available
Deep-dive analytics for ARD Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is ARD Podcast?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.